Delmitide (RDP58) 是一种 具有有效的抗炎活性的 d-异构体十肽，具有口服活性。Delmitide 抑制 TNF-α、IFN-γ 和白细胞介素 (IL)-12 的产生，并上调血红素加氧酶 1 的活性。Delmitide 可用于溃疡性结肠炎的研究。
| 生物活性 | Delmitide (RDP58) is an orally active d-isomer decapeptide with potentanti-inflammatoryactivity. Delmitide inhibits production of TNF-α,IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide can be used for the research of ulcerative colitis[1][2]. |
体内研究
(In Vivo) | Delmitide (oral; 2.5, 5, 10 mg/kg; daily) significantly reduced CPT-11induced diarrhea, mucosal inflammation, and mortality in mice by suppressing the overproduction of proinflammatory cytokines TNF-a, IFN-y, and IL-12 in vivo[2].
Delmitide (oral; 2.5, 5, 10 mg/kg; daily) generates an enhanced tumor response and prolongation of time to relapse without concomitant Gl toxicity in mice[2].
| Animal Model: | BALB/c mice (female, 9-10-week)[2] | | Dosage: | 2.5, 5, 10 mg/kg or 0.2 mL, 10 mg/kg | | Administration: | Oral, daily | | Result: | Reduced the incidence of diarrhea and attenuated CPT-11-associated GI toxicity and mortality in a dose-dependent manner.
Had protective effect against chemotherapy-induced GI side-effects and reduced CPT-11-induced overexpression of TNF-α, IFN-γ, and IL-12 in vivo.
Preserved the intestinal mucosa morphology by maintaining villus and crypt structure and inhibited TNF-α-mediated apoptosis in the crypt compartment, thereby protecting intestinal mucosa integrity in mice.
Protected mice from CPT-11-induced GI toxicity and mortality and enhanced animal survival in tumor-bearing mice.
Significantly reduced the incidence and overall tumor burden in a spontaneously metastatic model. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| Sequence Shortening | D(R-Nle-Nle-Nle-R-Nle-Nle-Nle-GY-NH2) |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
